Limits...
Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.

Chater PI, Wilcox MD, Brownlee IA, Pearson JP - Carbohydr Polym (2015)

Bottom Line: Alginates were shown to reduce pepsin activity by up to 53.9% (±9.5SD) in vitro.Limited inhibition of trypsin was shown.Significant inhibition of proteolysis was shown in the gastric phase of digestion, but not the small intestinal phase.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address: peter.chater@ncl.ac.uk.

No MeSH data available.


Related in: MedlinePlus

Bovine serum albumin digestion in gastric phase of a model gut system with and without FMC3 Alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of FMC3. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of FMC3 alginate significantly inhibited the gastric digestion of protein by 52.8% (P = 0.004), 70.9% (P = 0.001499) and 73.06 (P = 0.01846) respectively (t-test).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4539341&req=5

fig0030: Bovine serum albumin digestion in gastric phase of a model gut system with and without FMC3 Alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of FMC3. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of FMC3 alginate significantly inhibited the gastric digestion of protein by 52.8% (P = 0.004), 70.9% (P = 0.001499) and 73.06 (P = 0.01846) respectively (t-test).

Mentions: FMC3 showed a similar inhibition profile to FMC13 (Fig. 6). At T[30], protein digestion was reduced by 51.9% (P = 0.0002), 69.6% (P = 0.013) and 48.0% (P = 0.016) with 125, 250 and 500 mg of FMC3 alginate, respectively. At T[45], protein digestion was reduced by 50.4% (P = 0.005), 64.0% (P = 0.015) and 47.2% (P = 0.0004) as compared to control with 125, 250 and 500 of FMC3 alginate, respectively. By the final timepoint at T[60], protein digestion was reduced by 20.2% (P = 0.029), 64.8% (P = 0.024) and 55.1% (P = 0.035) as compared to control with 125, 250 and 500 mg of FMC3 alginate, respectively.


Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.

Chater PI, Wilcox MD, Brownlee IA, Pearson JP - Carbohydr Polym (2015)

Bovine serum albumin digestion in gastric phase of a model gut system with and without FMC3 Alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of FMC3. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of FMC3 alginate significantly inhibited the gastric digestion of protein by 52.8% (P = 0.004), 70.9% (P = 0.001499) and 73.06 (P = 0.01846) respectively (t-test).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4539341&req=5

fig0030: Bovine serum albumin digestion in gastric phase of a model gut system with and without FMC3 Alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of FMC3. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of FMC3 alginate significantly inhibited the gastric digestion of protein by 52.8% (P = 0.004), 70.9% (P = 0.001499) and 73.06 (P = 0.01846) respectively (t-test).
Mentions: FMC3 showed a similar inhibition profile to FMC13 (Fig. 6). At T[30], protein digestion was reduced by 51.9% (P = 0.0002), 69.6% (P = 0.013) and 48.0% (P = 0.016) with 125, 250 and 500 mg of FMC3 alginate, respectively. At T[45], protein digestion was reduced by 50.4% (P = 0.005), 64.0% (P = 0.015) and 47.2% (P = 0.0004) as compared to control with 125, 250 and 500 of FMC3 alginate, respectively. By the final timepoint at T[60], protein digestion was reduced by 20.2% (P = 0.029), 64.8% (P = 0.024) and 55.1% (P = 0.035) as compared to control with 125, 250 and 500 mg of FMC3 alginate, respectively.

Bottom Line: Alginates were shown to reduce pepsin activity by up to 53.9% (±9.5SD) in vitro.Limited inhibition of trypsin was shown.Significant inhibition of proteolysis was shown in the gastric phase of digestion, but not the small intestinal phase.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address: peter.chater@ncl.ac.uk.

No MeSH data available.


Related in: MedlinePlus